Joint Corp (NASDAQ:JYNT)’s share price traded up 8.5% on Friday . The company traded as high as $2.31 and last traded at $2.31, with a volume of 62,607 shares traded. The stock had previously closed at $2.13.

A number of equities analysts have recently weighed in on the company. Maxim Group lowered their target price on Joint Corp from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, July 1st. Zacks Investment Research raised Joint Corp from a “sell” rating to a “hold” rating in a research report on Tuesday, July 19th. Finally, Feltl & Co. lowered Joint Corp from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 24th.

The company’s 50 day moving average price is $2.25 and its 200-day moving average price is $3.03. The company’s market capitalization is $30.52 million.

Joint Corp (NASDAQ:JYNT) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $5 million for the quarter, compared to the consensus estimate of $3.40 million. On average, equities research analysts anticipate that Joint Corp will post ($0.97) earnings per share for the current fiscal year.

In related news, major shareholder Glenhill Advisors Llc purchased 80,069 shares of Joint Corp stock in a transaction that occurred on Friday, July 1st. The shares were acquired at an average cost of $1.97 per share, for a total transaction of $157,735.93. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.